PER-079-07已完成未知
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PARALLEL GROUP TO DETERMINE IF, IN PATIENTS WITH TYPE 2 DIABETES WITH HIGH RISK OF CARDIOVASCULAR AND RENAL EVENTS, ALISKIREN, IN ADDITION TO CONVENTIONAL TREATMENT, REDUCES MORBIDITY AND CARDIOVASCULAR AND RENAL MORTALITY
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 87 人开始时间: 2007年11月12日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Patients with type 2 diabetes. Patients must be on current treatment with oral antidiabetics and / or insulin, or have fasting blood glucose at 7.0 mmol / l (126 mg / dL) or a blood glucose at 2 h at 11.1 mmol. / l (200 mg / dL) (WHO 2006a).
- •Male or female patients> 35 years of age.
- •Patients who give written informed consent to participate in the study after receiving a clear explanation of the purpose and nature of the investigation.
排除标准
- •Serum potassium> 5.0 mmol / L (in the visit immediately preceding Visit 3)
- •History of any cardiovascular event (CVA, TIA, IM, unstable angina, CABG, percutaneous coronary intervention, hospitalization for 10) during the 3 months prior to Visit 1. If a patient experiences one of these events between Visit 1 and the Randomization in Visit 3, he / she must be removed from the selection phase. If appropriate, the patient can re-participate in the selection at a later stage.
- •Hypertension (at Visit 3): any patient with a mean systolic blood pressure in sitting position (msSBP)> 135 and <170 mmHg or mean diastolic blood pressure in sitting position (msDBP) s 85 and <110 mmHg unless receiving treatment with at least 3 antihypertensive medications.
- •Hypertension (at Visit 3): any patient with a msSBP s 170 mmHg or msDBP> 110 mmHg
- •NYHA Class III and IV Congestive Heart Failure
- •Concomitant treatment with two (2) or more blocking agents of the renin-angiotensin aldosterone system, ex. lECA, BRA or aldosterone antagonists.
- •Unstable serum creatinine
- •Cardiac block of second (II) or third (111) degree without pacemaker
- •Potentially fatal concurrent arrhythmia or other uncontrolled arrhythmia
- •Clinically significant valvular heart disease
- •History of renal artery stenosis
- •Diabetes mellitus type 1 (defined as a disease that started before the age of 35 and requires permanent treatment with insulin during the first year of diagnosis).
- •Any medical or surgical condition that may significantly alter the absorption, distribution, metabolism or excretion of the study drugs, including any of the following, without being limited to these: • History of major surgery of the gastrointestinal tract such as gastrectomy, gastroenterostomy or resection intestinal (patients with previous bariatric surgery are allowed to participate> 6 months before Visit 1) • Any history of pancreatic injury, pancreatitis or evidence of deterioration / damage to pancreatic function indicated by an alteration of lipase or amyloid • Evidence of fetal disease determined by any of the following conditions: SGPT value above 3 x Upper Normal Limit (ULN) at Visit 1, history of hepatic encephalopathy, antecedent cirrhosis, esophageal varices or antecedent portocava shunt.
- •History of malignant tumors other than basal cell skin cancer in the last two years.
- •Any life-threatening condition with a life expectancy of less than 2 years.
- •History or evidence of drug or alcohol abuse in the last 12 months
- •Any concurrent medical or surgical condition that, in the opinion of the investigator, may expose the patient to a greater risk if he or she participates in the study, or that probably prevents the patient from meeting the requirements of the study or preventing the patient from completing the study.
- •History of hypersensitivity to any of the study drugs or to medicines belonging to the same therapeutic class of the study drug, including a history of allergy to BRAs or to lECAs as well as antecedent or suspected contraindications to the study drugs.
- •History of non-compliance with medical treatments or lack of will to comply with the study protocol.
- •Use of other investigational drugs at the time of recruitment, in the 30 days or 5 half-lives prior to recruitment, or whichever is greater.
- •Any condition that, in the opinion of the investigator or the Novartis medical monitor, could jeop
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82